Design Therapeutics (DSGN) Stock: Buy, Sell, or Hold?
DSGN - Design Therapeutics, Inc. Common Stock
$10.73
-0.37 (-3.33%)
▼
5d:
+10.28%
30d:
-18.47%
90d:
-7.74%
BUY
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When DSGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DSGN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DSGN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DSGN is currently trading at $10.73, which is considered oversold relative to its 30-day fair value range of $10.84 to $12.79.
Technical Outlook: Technically, DSGN is showing sideways momentum. Immediate support is located at $9.47, while resistance sits at $11.92. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: DSGN scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $21.71 (+102.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DSGN is showing sideways momentum. Immediate support is located at $9.47, while resistance sits at $11.92. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: DSGN scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $21.71 (+102.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.84 -
$12.79
Company Quality Score
55/100
(HOLD)
Options IV Signal
42th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
85.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 42th percentile)
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 102.4% below Wall St target ($21.71)
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$10.84 -
$12.79
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.24
(20.9%)
Support & Resistance Levels
Support Level
$9.48
Resistance Level
$11.92
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.63
Wall Street Target
$21.71
(+102.4%)
Share & Embed Analysis
Last updated: October 22, 2026 9:12 AM ET
Data refreshes hourly during market hours. Next update: 10:12 AM
Data refreshes hourly during market hours. Next update: 10:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DSGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 71 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 47 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 71 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 50 HOLD |
